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Comparison of the Activity of Free and Liposomal Amphotericin B In Vitro and
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Because of the toxicity of amphotericin B-desoxycholate (AmB-d) during systemic therapy,
less toxic forms of AmB, which promise to havea broader therapeutic index, are under investiga-
tion. There is, however, no convincing explanation of how such preparations might be made less
toxic yet retain their antifungal efficacy. In this study, the antifungal activity of a less toxic,
unilamellar liposomal (I) preparation of AmB (AmBisome), which is commercially available in
some countries, was compared with conventional AmB-d in vitro and in models of systemic and
localized candidiasis in immunosuppressed mice. Results indicate that lAmB has four to eight
times less antifungal activity than AmB-d in all experimental settings tested. Because lAmB is
significantly less active, the therapeutic index of such preparations must be tested clinically
before their use can be recommended solely on the basis of toxicity data.
More than 30 years after its introduction into clinical prac-
tice, amphotericin B (AmB) remains the most important an-
tifungal agent for the treatment ofmost invasive mycoses [1].
Because of the considerable toxicity of AmB [1-3], which
limits its maximal dosage in humans to 1.5 mg/kg/day, less
toxic alternatives are sought. Attempts have been made to
lower AmB toxicity by entrapping it in liposomes [4-8],
complexing it with lipids [9-12], or administering Amls-de-
soxycholate (AmB-d) in a lipid emulsion [13-16]. However,
it is the potential of AmB to preferentially bind to ergosterol
rather than to cholesterol that is the key to understanding its
fungicidal and toxic activity [17-19]. This chemical property
of AmB is not altered by its formulation. Although it has
been hypothesized that alternate formulations ofAmB might
favorably affect its therapeutic index [12, 20, 21], these
claims have not been substantiated in clinical studies, New
formulations of AmB have, however, been found to be less
toxic [8, 9, 13, 22, 23].
In this study, we investigated, in models of experimental
murine candidiasis, whether a liposomal preparation ofAmB
(lAmB), while less toxic, would also be less active than
AmB-d. Since hematogenous infections of parenchymatous
organs and a secluded infection could differ in their response
to therapy with free and lAmB, the therapeutic response was
studied in two models: systemic candidiasis after intravenous
(iv) infection and localized candidiasis in a subcutaneous
pouch [24, 25]. We reduced possible interference of thera-
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peutic effects with host immunity by immunosuppression
with cortisone, which prevents elimination of candidae by
host defense mechanisms in this model [25].
Materials and Methods
Animals. Female ICR mice (Institut fur Tierzucht, Univer-
sity of Zurich; 6-8 weeks old; average weight, 25g) were held in
groups of 8 and given free access to food pellets and acidified
water.
Organisms. Single lots of Candida albicans SD I, [24, 25],
NCI9, NC31, and SN35 (gift from A. Polak, Hoffmann-La
Roche, Basel, Switzerland), isolated from patients with funge-
mia, were stored at -70°C and propagated overnight at 37°C in
50 mL of tryptic soy broth (TSB; Difco, Detroit). Beforeuse, the
isolates were washed three times in 0.9%saline and then diluted
in 0.9% saline to desired concentrations. Yeast cells were
counted with a hemocytometer, and the inoculum size was veri-
fied by quantitative culture ofserial dilutions on tryptic soy agar
(TSA; Difco).
Immunosuppression. For immunosuppression, mice re-
ceived 5 mg of cortisone acetate (Sigma, St. Louis) subcutane-
ously in 0.9% saline 2 days and immediately before challenge
[24, 25].
Models ofinfection. For disseminated infection, 104 to 7.5 X
105 yeast cells suspended in 0.5 mL of 0.9% saline were inocu-
lated into the lateral tail vein. For studies of local candidiasis,
pneumatized subcutaneous pouches were formed 5 days before
challenge as described previously [25]. Briefly, 3-4 mL of air
was injected in the back region through a hypodermic needle
into the subcutis. To keep pouches pneumatized, air (usually
0.5-1 mL) was reinjected as required during the study. Cysts
were challenged with r- 106 yeast cells suspended in 0.2 mL of
0.9%saline.
Antifungal regimens. AmB (Fungizone; Bristol-Myers Squibb,
Princeton, NJ), consisting of 50 mg of AmB plus 41 mg of des-
oxycholate, was dissolved in 10 mL of sterile water as a stock
solution and then diluted further in 5% dextrose. AmB-d in a
dose c I mg (active drug)/kg was given in a single daily injec-
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NOTE. Data are no. mice dead/no. inoculated. NO, not done.
* Given as fractionated doses (:.;;;; I mg/kg) 4 h apart. With this regimen,
mice receiving 3 mg/kg/day died within 36 to 72 h of first dose.
Dose of AmB (rug/kg) AmB-d* IAmB
8 NO 0/8
4 NO 0/8
3 8/8 0/8
2 0/8 0/8
I 0/8 NO
Table 2. Toxicity of amphotericin B-desoxycholate (AmB-d)
and liposomalamphotericin B(lAmB) given to immunosuppressed
mice daily for 6 days.
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Figure 1. Antifungal activity of amphotericin B-desoxycholate
(AmB-d) and Iiposomal amphotericin B (I-AmB) in vitro: 106 cfu/
mL Candida albicans SD I was incubated 24 h in medium with
graded concentrations of AmB-d and I-AmBbefore quantification.
Results are from I of 2 representative experiments.
Statistical analysis. Results are given as mean ± SD from
3-5 animals per group and time point. Values were compared
by Student's t test.
Results
tion into the lateral tail vein. Larger doses were divided (~I
mg/kg/dose) and given 4 h apart. lAmB (AmBisome; gift of
Vestar, San Dimas, CA) was reconstituted according to the man-
ufacturer's recommendations. Stock solutions were stored at
4°C up to I week. For iv injection, the IAmB was diluted in 5%
dextrose to the required concentrations and given iv in a single
daily dosage. Treatment was started 6 h after challenge and was
continued until sacrifice.
Evaluation ofthe effect ofantimycotic regimens. The animals
were sacrificed by exposure to CO2 , and the yeast infection was
quantitated by culturing serial dilutions of homogenates, which
were prepared from subcutaneous pouches and parenchymatous
organs by individual homogenization with Teflon pestles as de-
scribed previously [25].
In vitro comparison of the fungicidal activity of ArnB
formulations. For in vitro studies, an overnight culture of test
strains grown in TSB were washed in MEM (Life Technologies
GIBCO BRL, Basel, Switzerland) and visually adjusted to a con-
centration of 106 yeast cells/rnl. before exposure to graded con-
centrations (0-50 mg/L) ofAmB-d and lAmB. After incubation
for 24 h in a 5%CO 2 atmosphere, yeast cells were washed three
times in TSB, and serial dilutions were cultured in duplicate on
TSA for quantification of colony-forming units.
Table 1. Fungicidal activity of amphotericin B-desoxycholate
(AmB-d) and liposomal amphotericin B (lAmB) against 4 isolates
of Candida albieans in vitro.
Strain AmB-d IAmB Ratio of IAmB to AmB-d
SOl 0.67 3.4 5.0
NC31 0.76 6.9 9.1
NCI9 0.75 2.9 3.9
SN35 0.35 2.9 8.3
NOTE. Data are concentration (mg/L) required to reduce initial inocu-
lum ( 106 cfu) of yeast cells by 2 logs (99% killing).
Comparison ofthe fungicidal activity ofAmB-d and lAmB in
vitro. At concentrations of 0.2 and 0.8 mg/L, respectively,
AmB-d and lAmB were fungistatic; 99% killing was seen at
concentrations <0.4 mg/L AmB-d and at 3.2 mg/L lAmB.
Both results show that lAmB is four to eight times less active
than AmB-d in vitro (figure I). Comparable results were ob-
tained with other C. albicans isolates (table I) and when the
technique was modified by placing test tubes on a rotary
shaker for agitation during exposure of fungus cells to AmB
(data not shown).
Toxicity ofAmB-d and lAmB in mice. In preparation of
the therapeutic in vivo studies, the toxicity of both AmB
formulations was compared in mice receiving the immuno-
suppressive cortisone regimen (see Materials and Methods).
Table 3. Change in colony-forming units of 2 strains of Candida
albicans in pneumatized pouches of immunosuppressed mice after
3-day treatment with amphotericin B-desoxycholate (AmB-d) or
liposomal amphotericin B (lAmB).
AmB-d Change IAmB Change
(mg/kg/day) (log cfu) (mg/kg/day) (log cfu)
C. albieansSO I
None +0.94 (±0.06) 2 +0.53 (±0.42)
I -0.21 (±0.39) 4 0.05 (±0.34)
2 -0.68 (±0.43)* 8 -0.30 (±0.40)
c.albieansNC I9
None + 1.01 (±O.41) 2 -0.06 (±0.36)
I -0.79 (±0.36) 4 -0.06 (±O.26)
2 -1.53 (±0.46)* 8 -1.42 (±O.44)
NOTE. Treatment was started 6 h after challenge with 106 yeast cells
and was followed by further doses 30 and 54 h after challenge. Mice were
sacrificed 24 h after last therapeutic dose. Mean ± SO from 3-5 mice/group.
* Antifungal activity was significantly higher than that of 4 mg oflAmB (P
< .01).
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Figure 2. Antifungal activity of amphotericin B-desoxycholate
(AmB-d) and liposomal amphotericin B (I-Am B) in pneumatized
subcutaneous pouches. After immunosuppression with 5 mg ofcor-
tisone twice. 1.2 X 106 cfu of Candida albicans SD 1 was inoculated
into pouches. Mean ± SD from 4 mice per group and time point.
Injections ofgraded doses (milligrams per kilogram) ofAmB
(active drug) were given. Mice died within 90 min of injec-
tion if given> I mg of AmB-d in an unfractionated dose;
therefore. higher daily doses were divided into amounts ~ I
mg/kg and given 4 h apart. With this regimen. the mice re-
ceiving 3 mg/kg/day died 36-72 h after the first injection.
Mice tolerated much higher doses of lAmB than AmB-d.
The highest tolerated dosage of Amls-d was 2 mg/kg/day
(table 2).
Comparison of AmB-d and IAmB in a model of local
candidiasis. In a first series of experiments with 2 strains of
C. albicans. AmB-d given for 3 days was four to eight times
more active against C. albicans on a dose per weight basis
than was lAmB (table 3). Treatment for 7 days after inocula-
tion of 1.2 X 106 cfu of C. albicans into subcutaneous
pouches further widened the discrepancy between the anti-
fungal activity of the two formulations. In all groups ofmice.
all doses studied resulted in a reduction of colony-forming
units by day 7, which was also 7 days after the last immuno-
suppression with cortisone acetate. In addition. 2 mg/kg
AmB-d proved more active than 8 mg/kg IAmB (P = .0594),
and I mg/kg AmB-d had an effect comparable to 8 mg/kg
lAmB (figure 2). Thus. lAmB appeared about four to eight
times less potent than AmB-d in the local model of candi-
diasis.
Comparison of AmB-d and lAmB in a model of systemic
candidiasis. In the systemic model, I mg/kg AmB-d was
more active than 2 and 4 mg/kg IAmB against C. albicans in
the kidneys (P = .0013; figure 3A). After a higher inoculum
ofC. albicans (see figure 3B). considerably larger numbers of
colony-forming units were recovered from the kidneys. At
0.5 rng/kg, AmB-d showed antifungal activity comparable to
4 mg/kg lAmB. For the higher doses of AmB-d (l and 2
mg/kg), the ratio of its antifungal potency compared with
IAmB was -1:8 (figure 3B).
In all experiments with the systemic model ofcandidiasis,
a much lower number of fungi was recovered from the livers
than the kidneys because C. albicans was rapidly cleared
from this organ despite immunosuppression with cortisone.
Therefore, a comparison of the therapeutic activity of the
two formulations was only possible on day I, which was I
day after challenge and after only I dose of AmB. Treatment
with different concentrations of AmB-d suggested a dose-ef-
fect relationship, and even the lowest dose (0.5 mg/kg) of
AmB-d had antifungal activity. IAmB at doses of 4-16 mg/
kg was not more active than 0.5 mg/kg Amls-d, and no defin-
itive dose response was obtained for lAmB (table 4).
Discussion
These studies show that IAmB, while considerably less
toxic. is four to eight times less active than AmB-d in vitro
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Figure 3. ~ntifungal acti~ity ofamphotericin B-desoxycholate (AmB-d) and liposomal amphotericin B (I-AmB) in kidneys ofimrnuno-
supp~essed ~Ice challenged intravenously with 104 cfu (A) or 7.5 X lOS cfu (B) ofCandida a/bieans SO I. Mean ± SO from 4 mice per group
and time point.
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Table 4. Number of colony-forming units of Candida albicans
SD 1 after I day of treatment with amphotericin B-desoxycholate
(AmB-d) or liposomal amphotericin B(lAmB) in livers ofimmuno-
suppressed mice.
AmB-d IAmB
(mg/kg) Log cfu (mg/kg) Log cfu
None 4.67 (±0.06) None 4.67 (±0.06)
0.5 3.05 (±0.25) 4.0 2.94 (±0.38)
1.0 2.89 (±0.18) 8.0 2.82 (±0.43)
2.0 2.59 (±0.19) 16.0 2.87 (±0.48)
NOTE. Intravenous challenge dose was 7.5 X lOscfu. Mean ± SO from
4 mice/group.
and in vivo. Not surprisingly, a localized infection with C.
albicans in subcutaneous pouches was difficult to treat, and
compared with the treatment of systemic candidiasis, it re-
quired more and higher doses ofAmB for an adequate thera-
peutic effect. Surprisingly, however, there was no difference
between the ratio of activity of AmB-d and lAmB in the
models of localized or systemic candidiasis. The observation
that lAmB was less active both in vitro and in the animal
models indicates that the less toxic polyene antifungal drug
entrapped in liposomes is also therapeutically less active.
Therefore, we must question whether the therapeutic index
of the lAmB preparation studied here is indeed increased
over that of AmB-d.
Previous observations on the relative activity of liposomal
and free AmB in vitro remain controversial: Several investi-
gators have found an equivalent activity [26, 27], while
others have found a significantly lower activity [28-32] for
lAmB. Most in vivo studies indicate that lAmB, while less
toxic than AmB-d, is also less active at equal doses [4, 33-
37]. It has, however, been claimed in these studies, on the
basis of acute toxicity of rapidly injected AmB-d in small
laboratory animals, that the therapeutic index for lAmB is
better than for AmB-d. These studies do not, however, con-
sider that AmB-d is not given clinically as an iv bolus. In this
and previous (38] studies, mice tolerated much higher AmB-
d doses if the drug was given in multiple fractions. In mice,
the activity of the maximally tolerated dosage (2 mg/kg/day)
of AmB-d could not be reached by 8-16 mg/kg/day lAmB.
In conclusion, the lAmB used here was less toxic than
AmB-d, but it was also considerably less active. Therefore,
the therapeutic index of lAmB and possibly other new for-
mulations of AmB should be thoroughly evaluated before a
widespread clinical use of lAmB can be recommended. The
data also suggest that in such studies, lAmB should be tested
at higher doses than the usual doses of AmB-d.
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